Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Biotech
OSE's ulcerative colitis prospect improves symptoms in phase 2
Around one year after the French drugmakers split up, OSE has reported midphase data on its anti-IL-7 antibody lusvertikimab in ulcerative colitis.
Nick Paul Taylor
Jul 24, 2024 8:23am
Lilly inks $3.2B Morphic buyout to take on Takeda in IBD
Jul 8, 2024 8:20am
Palisade's ulcerative colitis drug prevents symptoms in mice
May 23, 2024 4:30am
AltruBio raises $225M for midphase ulcerative colitis program
May 21, 2024 8:00am
Prometheus team returns with brand-new biotech and $400M
Mar 21, 2024 7:00am
Aclaris lays off 46%, resurrects zunsemetinib for cancer
Dec 20, 2023 6:09am
